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Abstract
Multiple factors have been proposed as being responsible for cardiac damage in 
the context of obesity, including aldosterone/mineralocorticoid receptor and leptin. 
Aldosterone exerts proinflammatory, prooxidant and profibrotic actions, which 
can play a key role in the development of cardiac damage associated with different 
pathologies, through binding of mineralocorticoid receptor (MR). Moreover, its 
pharmacological blockade has demonstrated to improve these situations. Different 
studies have demonstrated that aldosterone is inappropriately elevated in obesity 
and MR antagonism improves left ventricle function and reduces circulating 
procollagen levels in patients with obesity without other comorbidities. Leptin is 
locally produced in the myocardium and its production is up-regulated in obesity. 
This adipokine is a proinflammatory, prooxidant and profibrotic factor that can 
participate in the cardiac damage associated with obesity. Interactions among leptin 
and aldosterone have previously been reported in different scenarios and at dif-
ferent levels, supporting a link between leptin and MR and that could result in the 
potentiation of the cardiac damage associated with obesity. Therefore, the aim of 
this review is to discuss whether MR activation can mediate the deleterious effects 
of leptin in the heart in the context of obesity, as well as the potential mechanisms 
involved in this process.
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1. Cardiac effects of obesity
Obesity has become a global problem of the first magnitude worldwide and 
is associated with an increase in total mortality, especially that of cardiovascular 
origin [1]. Obesity is an exaggeration of normal adiposity and plays a central role in 
the pathophysiology of various diseases such as type 2 diabetes mellitus, cardiovas-
cular disease, stroke, hypertension, and dyslipidemia [2]. Obesity is associated with 
several structural and function alterations in the heart which are characterized by 
cardiac hypertrophy and left ventricle systolic and diastolic dysfunction that con-
tribute to the development of heart failure [3]. There have been reported changes 
in left ventricle geometry in obese individuals, with these being more prevalent in 
an eccentric pattern defined by an increase in left ventricle mass but not in relative 
parietal thickness [4]. This cardiac hypertrophy could be a consequence of higher 
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metabolic demand required by obese individuals, as well as increased cardiac output 
which is associated with higher ventricular filling and which promotes ventricular 
dilatation and, in consequence, an enlargement of myocardial mass [5]. It is well 
known that left ventricular hypertrophy is a risk factor for heart failure develop-
ment [6]. Diastolic dysfunction is the main functional alteration observed in obese 
patients [7]. Ventricular hypertrophy along with an increase in blood flow and 
circulating volume predisposes to diastolic dysfunction observed in obese patients 
[4]. Pascual et al. reported subclinical left ventricular diastolic dysfunction in all 
degrees of obesity (mildly, moderate, and severely obese patients) [8]. Another 
study reported that the severity of the diastolic dysfunction observed in obesity 
increases proportionally with the body mass index [9]. Conflicting results have 
been found [8, 10–14] with regard to systolic function in obese individuals. These 
contradictory effects on systolic function could be consequence of the presence or 
not of comorbidities frequently associated with obesity (hypertension, metabolic 
disorders, and coronary artery disease) which can also have an impact on cardiac 
function. Several studies have postulated that perivascular and interstitial fibrosis 
could contribute to the cardiac dysfunction, especially diastolic one, observed in 
obesity [15]. Cardiac fibrosis is characterized by increased deposit of extracellular 
matrix (ECM) proteins in the myocardium. This is a dynamic process regulated by 
the balance between the synthesis and degradation of the ECM proteins within the 
heart. Collagen, especially collagen type I, is the main protein involved in fibrotic 
process, and metalloproteinases (MMPs) are the enzymes involved in ECM protein 
degradation. It has been described that obese patients present elevated serum levels 
of collagen peptides and are associated with indices of insulin resistance and with 
diastolic dysfunction [16, 17]. Moreover, the reduction in body mass index after 
bariatric surgery is not always accompanied by the normalization of diastolic func-
tion suggesting myocardial damage probably due to the accumulation of ECM [4].
Several mechanisms and factors have been proposed for the structural and 
functional changes that occur in the obese heart, such as, the effects of aldosterone, 
through mineralocorticoid receptor (MR) binding, and leptin, two hormones whose 
levels are increased in the context of obesity. Aldosterone/MR and leptin promote 
cardiac damage through its prooxidant and proinflammatory effects which can trigger 
an excessive ECM accumulation, promoting fibrogenic and hypertrophic responses 
and functional alterations [18–20]. We herein review the MR and leptin effects at 
cardiac level with special focus on the context of obesity as well as the interaction of 
aldosterone and leptin and its role in the development of cardiac remodeling.
2. Cardiac effects of mineralocorticoid receptor
Aldosterone is the main mineralocorticoid hormone, which plays an important 
role in the pathophysiology of cardiovascular disease through its binding to MR, 
which resides in the cytosol and is translocated to the nucleus after ligand bind-
ing, thereby promoting gene transcription [21]. Besides the hypertensive and the 
renal effects of aldosterone, chronic hyperaldosteronism promotes cardiovascular 
complications, including left ventricular hypertrophy, myocardial infarction, and 
atrial fibrillation [22]. The deleterious effects of aldosterone have traditionally been 
considered over the years due to its effects on sodium/water retention and its effects 
on blood pressure. However, its extrarenal effects through MR activation in non-
epithelial cells of the cardiovascular system have been confirmed in recent years [23]. 
Several clinical studies have demonstrated that the activation of MR plays an impor-
tant role in mild to severe heart failure [24–26]. MR blockade through MR antagonists 
(MRA) reduces morbidity and mortality in heart failure patients. MRA treatment 
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has demonstrated beneficial effects at cardiac level even in the absence of aldosterone 
level modifications [24–26]. In accordance with these observations, the effects of MR 
by genetic modulation in different cell types have been demonstrated. Specifically, 
MR overexpression in cardiomyocytes leads to cardiac arrhythmias in mice in the 
absence of changes in aldosterone levels [27], and this effect is accompanied by severe 
coronary endothelial dysfunction due at least in part to an increase in oxidative stress 
[28]. In addition, mice with MR genetic deletion in cardiomyocytes are resistant to 
developing cardiac fibrosis induced by deoxycorticosterone/salt (DOCA-salt) and do 
not show inflammatory cell infiltration after 8 weeks of treatment [29]. In another 
animal model of cardiac disease, Fraccarollo et al. have demonstrated that MR dele-
tion in cardiomyocytes improved infarct healing, cardiac function, cardiac fibrosis, 
and mitochondrial superoxide anion production after myocardial infarction, which 
confirms the role of MR activation in cardiac cells in cardiac pathophysiology [30]. 
Similar beneficial effects on cardiac remodeling, hypertrophy, and profibrotic and 
proinflammatory markers have been observed in endothelial [31, 32] or macrophage 
[33] MR inactivation after DOCA-salt mineralocorticoid challenge and also in vascu-
lar smooth muscle MR inactivation in myocardial infarction [34].
In the context of obesity, clinical and experimental studies have demonstrated 
that aldosterone production is increased in obesity and is correlated with white adi-
pose tissue mass [35–37]. In addition, weight loss in obese individuals is accompa-
nied by a reduction in aldosterone levels [38]. Aldosterone is primarily synthesized 
in the outer layer of the adrenal cortex. However, it has been demonstrated that 
adipose tissue possesses the machinery necessary to produce aldosterone, which 
can act in an autocrine or paracrine manner [39]. Activation of renin-angiotensin-
aldosterone system has been reported in animal models of obesity [20, 40, 41]. 
Endothelial-specific MR deletion in female mice was able to prevent the diastolic 
dysfunction induced by high-fat diet [42]. This improvement was accompanied by 
a reduction in cardiac fibrosis, ECM protein deposition, cardiac inflammation, and 
oxidative stress as well as an improvement in insulin metabolic signaling [42]. These 
results were confirmed by the same research group where the administration of the 
MRA spironolactone reproduced the same results [43] in female mice fed with a 
high-fat diet as well as prevented the development of arterial stiffening in the ani-
mals [44]. In agreement with these findings, a randomized controlled clinical study 
has shown that aldosterone blockade with spironolactone for 6 months improved 
left ventricular function and reduced circulating procollagen peptide levels in obese 
patients without other comorbidities [45]. The addition of spironolactone to the 
standard treatment (angiotensin II inhibitors) was also able to improve left ventricle 
dysfunction and collagen turnover in patients with metabolic syndrome [46]. In 
a recent study, we have demonstrated that galectin-3, a lectin upregulated by MR 
activation, is increased in obese patients and its levels were associated with diastolic 
function [17]. In addition, pharmacological blockade of galectin-3 with an activity 
inhibitor blunted the cardiovascular remodeling and inflammation in obese male 
rats [17]. Another study in obese rats showed that the administration of spironolac-
tone normalized cardiac diastolic function and reduced cardiac fibrosis [47]. The 
studies performed in the context of obesity overall show the implication of MR in 
cardiac damage and the beneficial consequences of the use of MRA in the treatment 
of obesity-related cardiovascular dysfunction.
3. Cardiac effects of leptin
Leptin is the product of the ob gene that circulates in proportion to body fat 
[48]. This hormone is considered critical for informing the central nervous system 
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about the status of energy reserves and control satiety [49]. It is thought that obese 
people are leptin-resistant due to the lack of satiation observed. However, this 
leptin resistance does not occur in peripheral tissues, including the cardiovascular 
system, where leptin promotes several actions in obesity [50]. Leptin is mainly 
produced by adipose tissue, but it is also produced in different tissues, including 
the heart [48]. Plasma leptin levels have been considered to be an independent 
predictor of coronary heart disease [51] and a risk factor for myocardial infarc-
tion [52] and coronary atherosclerosis [53]. During obesity there is an increase 
in systemic leptin levels, as well as in the heart where it is locally produced [54]. 
Leptin acts via transmembrane receptors which are the product of db gene [55]. 
Genetic deletion of ob or db genes promotes obese animals, which have been used 
in conjunction with diet-induced obese animals in order to study the role of leptin 
in the cardiovascular system [56–58]. Several mechanisms have demonstrated the 
pathogenic role of leptin at cardiac level. Leptin receptor-deficient obese Zucker 
rats have been a studied animal model of hyperglycemia and diabetes [59], cardiac 
lipotoxicity [60], and diastolic cardiac dysfunction [61] as well. In accordance with 
this metabolic alterations, it has been demonstrated that leptin increased fatty 
acid uptake in HL-1 cells leading to intracellular lipid accumulation [62] being one 
possible mechanism involved in cardiac lipotoxicity that can facilitate the develop-
ment of heart failure [63].
Concerning structural modifications observed in obesity, clinical data have 
shown a positive correlation between plasma leptin levels with left ventricular 
hypertrophy [64]. Infusion of leptin in myocardial infarction mice increased left 
ventricle diameter as compared with animals without leptin infusion [65]. In vitro 
data show the direct hypertrophic effects of leptin inducing elongation of cardiac 
myocytes via the activation of JAK/STAT pathway [65]. Despite the well-established 
hypertrophic effects of leptin, there is one report that documented contradictory 
effects. Ob/ob mice have shown cardiac hypertrophy which is reverted after leptin 
repletion [66]. It is documented that oxidative stress plays an important role in 
the development of cardiac hypertrophy [67]. Leptin levels are correlated with 
superoxide anion levels in peripheral blood mononuclear cells from obese patients 
after adjusting for age and sex [68]. In this context, leptin produced an increase in 
reactive oxygen species (ROS) accumulation in a dose- and time-dependent manner 
in endothelial cells, accompanied by an activation of the JNK pathway [69]. Similar 
results have been observed in vascular smooth muscle cells [70] and in cardiac 
fibroblasts [54]. In addition, an antioxidant treatment in vascular and cardiac cells 
was able to prevent the increase in collagen production induced by leptin [54, 70],  
showing the role of oxidative stress in fibrogenic responses. Experimental studies 
have shown that leptin administration in ob/ob mice increased myocardial col-
lagen deposition, thus confirming its profibrotic effects [71]. Complementary 
techniques revealed cardiac interstitial fibrosis in db/db mice [72] and in Zucker 
rats [73], and it is associated with diastolic dysfunction. Multiple mechanisms have 
been suggested as being responsible for the interstitial fibrosis observed in these 
animals, including metabolic alterations and the activation of renin-angiotensin-
aldosterone system. However, the potential role of leptin in the aldosterone/MR 
activation observed in these animals is likely acting through mechanisms other than 
leptin, since both db/db mice and Zucker rats have impaired leptin signaling. These 
potential mechanisms could include angiotensin II, oxidative stress, or metabolic 
alterations [47, 74–76].
In a recent study, we have demonstrated that leptin enhances lysyl oxidase 
(LOX) protein levels in cardiac fibroblasts [77]. LOX is an ECM enzyme that 
catalyzes the cross-linking of collagen fibers [78]. The pharmacological inhibition 
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of LOX is able to prevent the increase in collagen production induced by leptin 
in cardiac and vascular cells as well as the cardiovascular fibrosis associated with 
obesity [77]. In addition, we have observed that leptin increased the aldosterone 
downstream product, galectin-3, protein levels in cardiac fibroblasts, which at the 
same time mediates the fibrotic effect of leptin [54] supporting the possible rela-
tionship between leptin and MR.
Another mechanism involved in cardiac injury in obesity is the inflammation 
[79]. Leptin can be considered to be an inflammatory cytokine itself [80] but also 
promotes monocyte recruitment [81] and macrophage foam cell formation [82] 
and promotes the secretion of another inflammatory cytokines [83]. The present 
knowledge of the mechanisms triggered by leptin has established the implication 
of this adipokine in the deleterious consequences of obesity in the cardiovascular 
system.
4. Leptin-aldosterone/MR axis
Leptin is a major stimulus to the production of aldosterone in obesity [41, 84]  
and may be responsible for the excessive MR signaling that is the hallmark of 
obesity-related heart failure [85, 86]. This thus supports a cross talk between 
leptin and MR, which can have deleterious consequences in the context of obesity 
including sodium balance. In this regard, visceral adiposity leads to positive sodium 
balance through the leptin receptor, which can cause sodium retention [87] through 
different mechanisms which include a direct action on the renal tubules, an increase 
in renal sympathetic nerve traffic [88, 89], and a direct stimulation of renin- 
angiotensin-aldosterone system [90, 91].
Obesity is associated with dysfunctional adipose tissue, which is characterized 
by the increase in the synthesis of different cytokines as well as leptin. In addition 
to leptin which is able to stimulate aldosterone synthesis and therefore active MR, 
whether other adipokines, such as, tumor necrosis factor-α, are able to increase 
aldosterone is not totally established in the literature since a variety of results have 
been reported [41, 92].
Leptin infusion in obese and lean mice promotes an increase in aldosterone 
plasma levels suggesting a relationship between both hormones [93]. Confirming 
these results, Huby et al. have demonstrated that there is an increase in aldosterone 
production in an animal model of leptin hypersensitivity due to an increase in 
CYP11B2 (aldosterone synthase) expression [90]. The authors showed in the same 
study that this increase in aldosterone and CYP11B2 is absent in three different 
transgenic models of leptin activity deletion [90]. In fact, leptin receptors are colo-
calized with CYP11B2 in human adrenal cells. In addition, the administration of the 
leptin receptor antagonist prevented the rise in aldosterone plasma levels observed 
in the leptin hypersensitivity animal model as well as in obese mice [94]. These 
data taken together demonstrate that aldosterone production induced by leptin is 
dependent on leptin signaling rather than on the increase in body weight. However, 
there are several discrepancies in this suggestion [95]. The mechanisms involved 
in aldosterone production induced by leptin are still unclear, although it has been 
proposed to be a calcium-dependent process. In human adrenocortical carcinoma 
cells, leptin increased calcium activity as well as CYP11B2 aldosterone production. 
When intracellular calcium is chelated, leptin-treated cells do not show the increase 
in CYP11B2 promoter activity [90].
Female mice infused with leptin presented reduced endothelium-dependent 
relaxation, which was prevented by spironolactone treatment—this demonstrates 
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that leptin induces endothelial dysfunction via MR [90]. In the same study, the 
authors showed that leptin administration for 7 days induced an increase in mRNA 
levels in profibrotic markers at cardiac level, which was blunted by treatment with 
spironolactone. This effect is independent of body weight since obese transgenic 
mice (ob/ob) only presented the increase in the profibrotic markers when they were 
treated with leptin [90]. The transgenic background could explain this effect since 
ob/ob mice are deficient in leptin, suggesting that leptin induced cardiac fibrosis 
through MR.
As it has been mentioned above, circulating leptin levels are increased in obe-
sity but also are increased locally at cardiac level [54]. In previous studies, we have 
demonstrated that leptin participates in collagen I production through its prooxi-
dant effects and suggests its possible role in the cardiac fibrosis associated with 
obesity [54]. Considering that mitochondria is the main source of ROS produc-
tion, we explored in a recent study the possible role of mitochondrial oxidative 
stress in cardiac alterations in obesity [40]. For this purpose, we used a normo-
tensive model of diet-induced obesity in rats treated with either MitoTEMPO (a 
mitochondrial ROS scavenger) or vehicle. The mitochondrial antioxidant was 
able to prevent the increase in superoxide anion production, as well as the cardiac 
hypertrophy and fibrosis in obese rats, thus showing the role of mitochondrial 
ROS in these alterations [40]. Interestingly, these effects of MitoTEMPO were 
accompanied by a reduction in leptin and aldosterone plasma levels in obese 
rats, suggesting a possible cross talk between both hormones. For this reason, we 
explored this possible interaction in cardiac myofibroblasts. In these cells, leptin 
increased CYP11B2 mRNA levels (Figure 1A) which was accompanied by an 
increase in the production of aldosterone in a dose- and time-dependent manner 
(Figure 1B and C).
In addition, leptin increased ECM proteins, profibrotic mediators, and the pro-
duction of superoxide anion at total and mitochondrial level through the activation of 
Akt and ERK1/ERK2 pathways [40]. The pharmacological blockade of MR through 
pretreatment of the cells with eplerenone was able to prevent all these alterations 
induced by leptin in the cardiac cells, thus showing the cross talk between MR and 
leptin. The results taken together show the possible role of leptin in cardiac fibrosis in 
the context of obesity through MR-dependent mechanisms (Figure 2) [40].
Figure 1. 
(A) Effects of leptin (100 ng/mL) on CYP11B2 mRNA levels at 24 hours of stimulation. (B) Dose-response 
and (C) time-course of leptin on aldosterone secretion in human cardiac fibroblasts. *p < 0.05; ***p < 0.001 vs. 
control.
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